RU2018135967A - Интраназальные фармацевтические композиции на основе бензодиазепина - Google Patents

Интраназальные фармацевтические композиции на основе бензодиазепина Download PDF

Info

Publication number
RU2018135967A
RU2018135967A RU2018135967A RU2018135967A RU2018135967A RU 2018135967 A RU2018135967 A RU 2018135967A RU 2018135967 A RU2018135967 A RU 2018135967A RU 2018135967 A RU2018135967 A RU 2018135967A RU 2018135967 A RU2018135967 A RU 2018135967A
Authority
RU
Russia
Prior art keywords
weight
methyl
pharmaceutical composition
composition according
diazepam
Prior art date
Application number
RU2018135967A
Other languages
English (en)
Russian (ru)
Inventor
Гари БРИМ
Моис А. КАЙРАЛЛАХ
Миоунг-Ки БАЕК
Дзае-Хоон ДЗО
Хие-Дзин ЧАНГ
Original Assignee
Акорда Терапьютикс, Инк.
ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акорда Терапьютикс, Инк., ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. filed Critical Акорда Терапьютикс, Инк.
Publication of RU2018135967A publication Critical patent/RU2018135967A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2018135967A 2011-03-31 2012-03-30 Интраназальные фармацевтические композиции на основе бензодиазепина RU2018135967A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161469940P 2011-03-31 2011-03-31
US61/469,940 2011-03-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2013148120/15A Division RU2013148120A (ru) 2011-03-31 2012-03-30 Интраназальные фармацевтические композиции на основе бензодиазепина

Publications (1)

Publication Number Publication Date
RU2018135967A true RU2018135967A (ru) 2018-11-14

Family

ID=46928023

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018135967A RU2018135967A (ru) 2011-03-31 2012-03-30 Интраназальные фармацевтические композиции на основе бензодиазепина
RU2013148120/15A RU2013148120A (ru) 2011-03-31 2012-03-30 Интраназальные фармацевтические композиции на основе бензодиазепина

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013148120/15A RU2013148120A (ru) 2011-03-31 2012-03-30 Интраназальные фармацевтические композиции на основе бензодиазепина

Country Status (15)

Country Link
US (3) US20120252793A1 (cg-RX-API-DMAC7.html)
EP (1) EP2691100A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014509655A (cg-RX-API-DMAC7.html)
KR (1) KR20140029426A (cg-RX-API-DMAC7.html)
CN (1) CN103619338B (cg-RX-API-DMAC7.html)
AR (1) AR085927A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012236334B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013024968A2 (cg-RX-API-DMAC7.html)
CA (1) CA2831308A1 (cg-RX-API-DMAC7.html)
MX (1) MX357800B (cg-RX-API-DMAC7.html)
PH (2) PH12013501915A1 (cg-RX-API-DMAC7.html)
RU (2) RU2018135967A (cg-RX-API-DMAC7.html)
SG (2) SG193958A1 (cg-RX-API-DMAC7.html)
TW (1) TWI601532B (cg-RX-API-DMAC7.html)
WO (1) WO2012135619A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP5929800B2 (ja) * 2012-04-03 2016-06-08 コニカミノルタ株式会社 定着液および画像形成方法
BR112019024987A2 (pt) 2017-06-02 2020-06-16 Xeris Pharmaceuticals, Inc. Formulações de fármaco de molécula pequena resistente à precipitação
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN111836615A (zh) 2018-01-05 2020-10-27 英倍尔药业股份有限公司 通过精密鼻装置的奥氮平的鼻内递送
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CA3102689C (en) 2018-06-04 2023-08-29 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
CN111529489A (zh) * 2020-04-17 2020-08-14 山东省药学科学院 一种含有地西泮的鼻腔喷雾剂
KR20230146513A (ko) 2020-12-04 2023-10-19 아큐티스 바이오테라퓨틱스, 인크. 항진균 특성을 갖는 국소 로플루밀라스트 제형
IL313866A (en) 2021-12-28 2024-08-01 Arcutis Biotherapeutics Inc Topical roflomilest spray foams
WO2024058848A1 (en) 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004578A (en) * 1996-10-24 1999-12-21 Alza Corporation Permeation enhances for transdermal drug delivery compositions, devices and methods
DE60038738T2 (de) * 1999-07-26 2009-07-02 Sk Holdings Co., Ltd. Transnasale anticonvulsive zusammensetzungen
EP1539285B2 (en) * 2002-09-03 2011-10-12 Pharmacure Health Care AB Nasal sprays
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US7745430B2 (en) * 2006-11-15 2010-06-29 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition
JP5539875B2 (ja) * 2007-08-31 2014-07-02 アルキメデス・デベロップメント・リミテッド 非水性医薬組成物
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
ES2440068T3 (es) * 2009-09-16 2014-01-27 Allergan, Inc. Compuestos para su uso en el tratamiento de trastornos convulsivos

Also Published As

Publication number Publication date
HK1195252A1 (zh) 2014-11-07
US20140128381A1 (en) 2014-05-08
CN103619338B (zh) 2016-06-22
WO2012135619A2 (en) 2012-10-04
EP2691100A4 (en) 2014-09-24
US20170151258A1 (en) 2017-06-01
WO2012135619A3 (en) 2012-11-22
EP2691100A2 (en) 2014-02-05
CA2831308A1 (en) 2012-10-04
PH12017501688A1 (en) 2018-09-10
KR20140029426A (ko) 2014-03-10
AU2012236334A1 (en) 2013-10-10
MX2013011336A (es) 2013-12-16
CN103619338A (zh) 2014-03-05
TW201302204A (zh) 2013-01-16
BR112013024968A2 (pt) 2016-12-20
US20120252793A1 (en) 2012-10-04
TWI601532B (zh) 2017-10-11
AU2012236334B2 (en) 2017-02-16
AR085927A1 (es) 2013-11-06
PH12013501915A1 (en) 2019-11-29
MX357800B (es) 2018-07-25
JP2014509655A (ja) 2014-04-21
SG10201602176RA (en) 2016-04-28
RU2013148120A (ru) 2015-05-10
SG193958A1 (en) 2013-11-29

Similar Documents

Publication Publication Date Title
RU2018135967A (ru) Интраназальные фармацевтические композиции на основе бензодиазепина
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
JP2014509655A5 (cg-RX-API-DMAC7.html)
IN2014MN01755A (cg-RX-API-DMAC7.html)
RU2015136849A (ru) Композиции, содержащие 15-он эпк, и способы их применения
PH12014502524B1 (en) Carboxylic acid compounds
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
EA201591195A1 (ru) Новые хинолоновые производные
PL2629754T3 (pl) Kompozycja farmaceutyczna w postaci ciekłej do podawania składników czynnych
MX354102B (es) Derivados de bencimidazol-prolina.
WO2012021715A3 (en) Stable formulations of linaclotide
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
JP2014218522A5 (cg-RX-API-DMAC7.html)
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
MX383762B (es) Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
ME02576B (me) Derivati tetrahidropirolotiazina kao inhibitori bace
EP2723177A4 (en) ADMINISTRATION OF PARAFFINOUS COMPOSITIONS TO THE ROOT TISSUE OF PLANTS
EP3228311A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
EA201492091A1 (ru) Фармацевтические композиции для местного применения, содержащие тербинафид и мочевину
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
HRP20171693T1 (hr) Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen
MY185947A (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20150331